Kyomed announces its selection, in conjunction with project leader Neogia and project partner Bluesleep clinic, as a finalist in the 2017 MedStartup awards.
Partners Kyomed, Neogia and Bluesleep nominated for clinical trial project on e-health device for sleep apnea
Montpellier, France, October 23, 2017 – Kyomed, a French clinical research organization providing services in personalized medicine, today announces its selection, in conjunction with project leader Neogia and project partner Bluesleep clinic, as a finalist in the 2017 MedStartup awards.
The collaboration on a connected solution for at-home diagnosis of sleep apnea, via a wearable device, has been nominated in the ‘Best Innovative Trial Design Leading to Quicker and Better Therapeutic Outcome’ category. Kyomed’s role will be to obtain clinical evidence of the efficacy and security of the device, in addition to evaluating feedback from patients and medical professionals. The CRO’s unique approach is to take into account the usability, acceptance and ergonomics of a device in clinical trial evaluations.
The MedStartup award, a joint initiative by the Galien Foundation and international development agency Business France, encourages and rewards partnerships between French and North American innovators in the life sciences industry. A panel of world-renowned scientific experts selected the Kyomed, Neogia and Bluesleep project along with two other finalists and will announce the winner in New York on October 26, 2017.
“It is a great honor for Kyomed to have been selected with Neogia as one of the three finalists in this category of the MedStartUp awards. This nomination alone is recognition of the high potential of our unique approach to conducting clinical trials of innovative medical devices,” said Daniel Laune, CEO and scientific director at Kyomed. “We are pioneering combined trials - clinical measures and user experience – to foster improved patient empowerment and engagement with new health technologies for better clinical evaluation outcomes. We are excited about our participation at the upcoming awards ceremony, which will mark Kyomed’s entry into the US market.”
The nominated Kyomed and Neogia medical device and clinical trials project centers around Neogia’s connected bracelet, Motio HW™. Rather than go to a doctor and wear impractical sensors for a whole night, sleep apnea patients will be able to use this easy-to-use wearable device as a wristband. It diagnoses and monitors sleep apnea at home by collecting biometrics data – oximetry, actimetry, heart rate and respiratory rate - and sends it to an application that is available on all platforms (smartphones/tablets/computers). A unique algorithm processes this data to better understand the sleeping profile of each patient and to improve quality of life.
Kyomed brought its expertise in clinical validation, medical device regulation and user experience evaluation to the project. The proof of concept trial will be held at the Bluesleep clinic in New York.
Kyomed and Neogia are planning to follow-up with a multicenter trial on the sleep apnea connected wristband in Europe and the US in H2 2018.
Kyomed will be exhibiting at the Scope Summit for Clinical Ops Executives (booth #109), February 12-15, 2018 in Orlando (FL) to meet with potential US partners and clients.
About Kyomed
Kyomed, a French CRO, offers integrative services to accelerate the development and market access of innovative products and services in the field of healthcare and autonomy. Kyomed’s achievements include the recent evaluation of the use and functionalities of a connected pillbox prototype developed by Sanofi and the coordination of a worldwide project to develop and assess a smartphone application for preventing, optimizing and personalizing the treatment of allergic rhinitis. Founded in 2014, the company employs 11 staff. It is located in Montpelier, France.
